Larimar Therapeutics, Inc. (LRMR) earnings
LRMR earnings moved a median of +1.31% by the close. Quarterly and annual LRMR reports and results, each read against the price at its own news timestamp. Back to the LRMR overview →
21 measured LRMR earnings events.
Where these LRMR earnings landedvs 21 measured LRMR earnings reactions
| Middle 50% of LRMR earnings reactions | -2.89% to +3.45% |
|---|---|
| Median reaction (to close) | +1.31% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 LRMR earnings events with a measured close landed between -2.89% and +3.45%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Larimar Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.00% | +3.27% | |
| Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update | Press release | -1.00% | +3.27% | |
| Form 10-Q Larimar Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.38% | -7.01% | |
| Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update | Press release | -3.87% | -6.04% | |
| Form 10-K Larimar Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.22% | -1.00% | |
| Form 10-Q Larimar Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +8.78% | |
| Larimar Therapeutics Reports Third Quarter 2025 Financial Results | Press release | -1.54% | -9.80% | |
| Form 10-Q Larimar Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.31% | +1.31% | |
| Larimar Therapeutics Reports Second Quarter 2025 Financial Results | Press release | +1.62% | +14.82% | |
| Form 10-Q Larimar Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -4.41% | +5.15% | |
| Larimar Therapeutics Reports First Quarter 2025 Financial Results | Press release | +1.04% | +10.42% | |
| Form 10-K Larimar Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.78% | +1.32% | |
| Form 10-Q Larimar Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.83% | -2.89% | |
| Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results | Press release | -2.32% | +3.30% | |
| Form 10-Q Larimar Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.27% | -1.20% | |
| Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results | Press release | -1.10% | -7.50% | |
| Form 10-Q Larimar Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.14% | -10.55% | |
| Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results | Press release | +1.66% | +0.51% | |
| Form 10-K Larimar Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.73% | +3.45% | |
| Form 10-Q Larimar Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.78% | -0.78% | |
| Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results | Press release | +2.08% | +6.67% |
Keep exploring
More LRMR: analyst actions → · SEC filings → · LRMR overview →